Chikungunya Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Funding
• Alerts
• Clinical Trials

Safety, Tolerability and Long-term Immunogenicity of Different Formulations of a Chikungunya Vaccine
Condition:   Chikungunya Virus Infection Interventions:   Biological: MV-CHIK lyophilised formulation, low dose;   Biological: MV-CHIK liquid frozen formulation, low dose;   Biological: MV-CHIK SPS® formulation, low dose;   Biological: MV-CHIK liquid frozen formulation, high dose;   Biological: MV-CHIK liquid frozen formulation, high dose and placebo Sponsors:   Themis Bioscience GmbH;   Celerion;   Assign Data Management and Biostatistics GmbH Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - August 17, 2018 Category: Research Source Type: clinical trials